Table 7.
shRNA transfectant or control sample | URE3-BP 5' oligo pair | P-value | URE3-BP middle oligo pair | P-value | URE3-BP 3' oligo pair | P-value |
---|---|---|---|---|---|---|
GFP | 100.0 ± 2.9 | -- | 100 ± 2.8 | -- | 100 ± 4.3 | -- |
HM1:IMSS | 106.4 ± 5.8 | 0.2928 | 108.9 ± 5.6 | 0.1008 | 102.8 ± 5.0 | 0.5792 |
URE3-BP (350–378) | 67.0 ± 2.5 | <0.0001 | 67.4 ± 2.0 | <0.0001 | 72.2 ± 2.8 | <0.0001 |
URE3-BP (580–608) | 12.4 ± 0.8 | <0.0001 | 13.5 ± 3.3 | <0.0001 | 12.5 ± 3.8 | <0.0001 |
The average URE3-BP transcript level as measured by qRT-PCR and normalized to actin was defined as being 100% in the GFP shRNA control transfectants. HM1:IMSS nontransfected amebae were also included. Three different oligo pairs amplifying the 5', middle, and 3' sections of URE3-BP were used (sequences and locations are shown in Table 3). Student's t test was used for statistical analysis. Three biological replicates were each assayed in quadruplicate with each oligo pair, with the exception of the HM1:IMSS samples, which had one biological replicate. Values are expressed as the percentage of URE3-BP mRNA of the GFP control shRNA transfectant level ± SE, with the P-value following each.